They identified the cellular origins of the FasL expression within the tumor microenvironment: in contrast to what was initially thought, FasL was not expressed at the surface of the tumor cells, but by endothelium cells, cancer-associated fibroblast (CAFs), and myeloid-derived suppressor cells (MDSC) [101,102,103]. Here, FASLG is linked to cancer.